Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares US Real Estate ETF
IYR
|
+$947M |
| 2 |
Tesla
TSLA
|
+$608M |
| 3 |
Microsoft
MSFT
|
+$444M |
| 4 |
Accenture
ACN
|
+$409M |
| 5 |
iShares MSCI Emerging Markets ETF
EEM
|
+$396M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CRH
CRH
|
+$2.06B |
| 2 |
Texas Instruments
TXN
|
+$1.92B |
| 3 |
Meta Platforms (Facebook)
META
|
+$1.81B |
| 4 |
Starbucks
SBUX
|
+$1.42B |
| 5 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$1,000M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.52% |
| 2 | Financials | 7.13% |
| 3 | Consumer Discretionary | 6.46% |
| 4 | Healthcare | 5.43% |
| 5 | Communication Services | 5.15% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3301
Tango Therapeutics
TNGX
$4.43B
| $972K | ﹤0.01% |
126,281
+55,470
| +78% | +$529K |
|
3302
Allogene Therapeutics
ALLO
$649M
| $960K | ﹤0.01% |
342,973
+172,745
| +101% | +$461K |
|
3303
Donegal Group Class A
DGICA
$731M
| $957K | ﹤0.01% |
64,952
+18,132
| +39% | +$261K |
|
3304
Altimmune
ALT
$552M
| $956K | ﹤0.01% |
155,741
+75,064
| +93% | +$509K |
|
|
ADAM
3305
Adamas Trust
ADAM
$815M
| $955K | ﹤0.01% |
150,946
+117,206
| +347% | +$754K |
|
3306
Equity Bancshares
EQBK
$1.04B
| $953K | ﹤0.01% |
23,308
+16,595
| +247% | +$647K |
|
3307
Vitesse Energy
VTS
$651M
| $949K | ﹤0.01% |
39,528
+30,243
| +326% | +$746K |
|
3308
Alphatec Holdings
ATEC
$1.46B
| $948K | ﹤0.01% |
170,546
+133,653
| +362% | +$1.03M |
|
3309
Paysafe
PSFE
$414M
| $946K | ﹤0.01% |
42,167
+30,881
| +274% | +$641K |
|
3310
Sutro Biopharma
STRO
$401M
| $945K | ﹤0.01% |
27,302
+21,676
| +385% | +$850K |
|
|
OLO
3311
DELISTED
Olo Inc
OLO
| $944K | ﹤0.01% |
190,335
+152,214
| +399% | +$753K |
|
3312
Stagwell
STGW
$2.07B
| $944K | ﹤0.01% |
134,421
+101,201
| +305% | +$693K |
|
3313
E.W. Scripps
SSP
$257M
| $940K | ﹤0.01% |
418,588
+394,580
| +1,644% | +$1.01M |
|
3314
Erasca
ERAS
$6.3B
| $939K | ﹤0.01% |
343,930
+296,657
| +628% | +$836K |
|
|
MRSN
3315
DELISTED
Mersana Therapeutics
MRSN
| $935K | ﹤0.01% |
19,781
+4,872
| +33% | +$215K |
|
3316
DoubleVerify
DV
$1.73B
| $934K | ﹤0.01% |
55,448
-53,447
| -49% | -$1.02M |
|
|
BBBY
3317
PUT
Bed Bath & Beyond
BBBY
$481M
| $930K | ﹤0.01% |
+101,530
| New | +$1.05M |
|
3318
Dillards
DDS
$9.19B
| $930K | ﹤0.01% |
2,424
+200
| +9% | +$76.3K |
|
3319
FuelCell Energy
FCEL
$1.73B
| $929K | ﹤0.01% |
81,516
-8,089
| -9% | -$120K |
|
3320
United Fire Group
UFCS
$1.32B
| $929K | ﹤0.01% |
44,380
+26,469
| +148% | +$548K |
|
3321
Costamare
CMRE
$1.88B
| $928K | ﹤0.01% |
59,016
+43,925
| +291% | +$633K |
|
3322
Xeris Biopharma Holdings
XERS
$1.39B
| $925K | ﹤0.01% |
324,472
+151,685
| +88% | +$390K |
|
|
LGF.A
3323
DELISTED
Lions Gate Entertainment Corp. Class A Voting Shares
LGF.A
| $923K | ﹤0.01% |
117,858
-16,585
| -12% | -$139K |
|
|
SAGE
3324
DELISTED
Sage Therapeutics
SAGE
| $923K | ﹤0.01% |
127,789
+49,171
| +63% | +$450K |
|
3325
Vaalco Energy
EGY
$570M
| $923K | ﹤0.01% |
160,736
+122,373
| +319% | +$771K |
|
Similar funds
Barclays's Q3 2024 Portfolio in Review
As of Q3 2024, Barclays held 5,593 positions worth $377B, up 15% from $327B the previous quarter. Its ten largest holdings account for 41% of the portfolio.
Barclays deployed $31.3B of net new capital in Q3 2024, opening 785 new positions and adding to 2,954 existing holdings. Its largest new stake was Smurfit Westrock: 3,460,710 shares worth $171M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 22% a quarter earlier, followed by Financials and Consumer Discretionary.
On the sell side, the largest reduction was CRH, an estimated $2.06B trimmed.
- Barclays's largest Q3 2024 buy was Smurfit Westrock: 3,460,710 shares worth $171M.
- Barclays added most to iShares US Real Estate ETF in Q3 2024, an estimated $947M increase.
- Barclays's biggest Q3 2024 reduction was CRH, cutting an estimated $2.06B.
- Barclays fully exited Equitrans Midstream Corporation Common Stock in Q3 2024, selling an estimated $51.3M.
- Barclays's ten largest holdings make up 41% of its $377B portfolio in Q3 2024.
- Barclays opened 785 new positions and closed 322 in Q3 2024.
- Barclays's portfolio value rose 15% quarter-over-quarter to $377B.
Based on Barclays's 13F filing for Q3 2024, filed 15 Nov 2024.